Citations

Showing 10 of 108119 citations.

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
Lipsyc-Sharf, Marla , Ou, Fang‐Shu , Yurgelun, Matthew B. , Schrag, Deborah , Dakhil, Shaker R. , Stella, Philip J., Weckstein, Douglas, Wender, Donald B., Faggen, Meredith, Heying, Erica N., Schuetz, Samantha R, Noble, Stephanie M., Meyerhardt, Jeffrey A. , Bekaii‐Saab, Tanios , Fuchs, Charles S. , Ng, Kimmie , Schrag, Deborah , Zemla, Tyler J, Noble, Stephanie, Meyerhardt, Jeffrey A , Fuchs, Charles S , Ng, Kimmie , Ou, Fang-Shu , Bekaii-Saab, Tanios S , Rubinson, Douglas Adam , Zemla, Tyler , Noble, Stephanie

Mayo Clinic

The Oncologist | January 1, 2022 | Volume: 27 | Issue: 4 | Pages: 292-298

10.1093/oncolo/oyab025 | PMID 35380713 Get It

Abstract Background Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC). It is unknown if adding bevacizumab improves outcomes. Patients and Methods In this multicenter, randomized, double-blind, placebo-controlled phase II trial, patients with irinotecan-refractory RAS-wildtype mCRC and no prior anti-EGFR therapy were randomized to cetuximab 500 mg/m2, bevacizumab 5 mg/kg, and irinotecan 180 mg/m2 (or previously tolerated dose) (CBI) versus cetuximab, irinotecan, and placebo (CI) every 2 weeks until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and adverse events (AEs). Results The study closed early after the accrual of 36 out of a planned 120 patients due to changes in funding. Nineteen patients were randomized to CBI and 17 to CI. Baseline characteristics were similar between arms. Median PFS was 9.7 versus 5.5 months for CBI and CI, respectively (1-sided log-rank P = .38; adjusted hazard ratio [HR] = 0.64; 95% confidence interval [CI], 0.25-1.66). Median OS was 19.7 versus 10.2 months for CBI and CI (1-sided log-rank P = .02; adjusted HR = 0.41; 95% CI, 0.15-1.09). ORR was 36.8% for CBI versus 11.8% for CI (P = .13). Grade 3 or higher AEs occurred in 47% of patients receiving CBI versus 35% for CI (P = .46). Conclusion In this prematurely discontinued trial, there was no significant difference in the primary endpoint of PFS between CBI and CI. There was a statistically significant improvement in OS in favor of CBI compared with CI. Further investigation of CBI for the treatment of irinotecan-refractory mCRC is warranted. Clinical Trial Registration: NCT02292758
Machine learning algorithm to predict anterior cruciate ligament revision demonstrates external validity
Martin, R. Kyle , Wastvedt, Solvejg , Pareek, Ayoosh , Persson, Andreas , Visnes, Håvard , Fenstad, Anne Marie , Wolfson, Julian , Moatshe, Gilbert , Wolfson, Julian , Lind, Martin , Engebretsen, Lars

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | January 1, 2022 | Volume: 30 | Issue: 2 | Pages: 368-375

10.1007/s00167-021-06828-w | PMID 34973096 Get It

AbstractPurposeExternal validation of machine learning predictive models is achieved through evaluation of model performance on different groups of patients than were used for algorithm development. This important step is uncommonly performed, inhibiting clinical translation of newly developed models. Machine learning analysis of the Norwegian Knee Ligament Register (NKLR) recently led to the development of a tool capable of estimating the risk of anterior cruciate ligament (ACL) revision (https://swastvedt.shinyapps.io/calculator_rev/). The purpose of this study was to determine the external validity of the NKLR model by assessing algorithm performance when applied to patients from the Danish Knee Ligament Registry (DKLR).MethodsThe primary outcome measure of the NKLR model was probability of revision ACL reconstruction within 1, 2, and/or 5 years. For external validation, all DKLR patients with complete data for the five variables required for NKLR prediction were included. The five variables included graft choice, femur fixation device, KOOS QOL score at surgery, years from injury to surgery, and age at surgery. Predicted revision probabilities were calculated for all DKLR patients. The model performance was assessed using the same metrics as the NKLR study: concordance and calibration.ResultsIn total, 10,922 DKLR patients were included for analysis. Average follow‐up time or time‐to‐revision was 8.4 (± 4.3) years and overall revision rate was 6.9%. Surgical technique trends (i.e., graft choice and fixation devices) and injury characteristics (i.e., concomitant meniscus and cartilage pathology) were dissimilar between registries. The model produced similar concordance when applied to the DKLR population compared to the original NKLR test data (DKLR: 0.68; NKLR: 0.68–0.69). Calibration was poorer for the DKLR population at one and five years post primary surgery but similar to the NKLR at two years.ConclusionThe NKLR machine learning algorithm demonstrated similar performance when applied to patients from the DKLR, suggesting that it is valid for application outside of the initial patient population. This represents the first machine learning model for predicting revision ACL reconstruction that has been externally validated. Clinicians can use this in‐clinic calculator to estimate revision risk at a patient specific level when discussing outcome expectations pre‐operatively. While encouraging, it should be noted that the performance of the model on patients undergoing ACL reconstruction outside of Scandinavia remains unknown.Level of evidenceIII.
Rational Second-Generation Antiandrogen Use in Prostate Cancer
Orme, Jacob J. , Pagliaro, Lance C. , Quevedo, J. Fernando , Park, Sean S. , Costello, Brian A. , Park, Sean S

Mayo Clinic

The Oncologist | January 1, 2022 | Volume: 27 | Issue: 2 | Pages: 110-124

10.1093/oncolo/oyab045 | PMID 35641216 Get It

Abstract The second-generation antiandrogens have achieved an ever-growing list of approvals and indications in subsets of prostate cancer. Here, we provide an overview of second-generation antiandrogen trials and FDA approvals and outline a rational sequencing approach for the use of these agents as they relate to chemotherapy and other available treatment modalities in advanced prostate cancer. All published phase II-III randomized controlled trials reporting outcomes with the use of second-generation antiandrogens in prostate cancer are included as well as all published trials and retrospective studies of second-generation antiandrogen sequencing and/or combinations. Complete tabular and graphical representation of all available evidence is provided regarding the use and sequencing of second-generation antiandrogens in prostate cancer. In metastatic castration-resistant prostate cancer, evidence suggests prioritization of abiraterone before chemotherapy, chemotherapy after second-generation antiandrogen failure, and postchemotherapy enzalutamide in select patients to maximize agent efficacy and tolerability. We conclude that a rational, optimized sequencing of second-generation antiandrogens with other treatment options is feasible with present data.
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Gregory, Gareth P. , Kumar, Shaji , Mahadevan, Daruka , Walker, Patricia , Wagner‐Johnston, Nina D. , Bannerji, Rajat , Bhutani, Divaya , Chang, Julie , Hernandez‐Ilizaliturri, Francisco J. , Klein, Andreas K. , Pagel, John M. , Rybka, Witold B. , Mohrbacher, Anne, Huang, Mo , Farooqui, Mohammed, Marinello, Patricia, Wagner-Johnston, Nina , Bannerji, Rajat , Bhutani, Divaya , Rybka, Witold , Yee, Andrew J , Huang, Mo , Quach, Hang , Wang, Ding , Escobar, Carolina, Mohrbacher, Ann M., Quach, Hang

Mayo Clinic

Blood Advances | December 31, 2021 | Volume: 6 | Issue: 4 | Pages: 1232-1242

10.1182/bloodadvances.2021005872 | PMID 34972202 Get It

AbstractPreclinical data demonstrated that combining an anti–programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were ≥18 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patients received pembrolizumab 200 mg every 3 weeks plus dinaciclib 7 mg/m2 on day 1 and 10 mg/m2 on day 8 of cycle 1 and 14 mg/m2 on days 1 and 8 of cycles 2 and later. Primary endpoint was safety, and a key secondary endpoint was objective response rate (ORR). Seventy-two patients were enrolled and received ≥1 dose of study treatment (CLL, n = 17; DLBCL, n = 38; MM, n = 17). Pembrolizumab plus dinaciclib was generally well tolerated and produced no unexpected toxicities. The ORRs were 29.4% (5/17, rrCLL), 21.1% (8/38, rrDLBCL), and 0% (0/17, rrMM), respectively. At data cutoff, all 72 patients had discontinued treatment, 38 (52.8%) because of progressive disease. These findings demonstrate activity with combination pembrolizumab plus dinaciclib and suggest that a careful and comprehensive approach to explore anti–PD-1 and CDK9 inhibitor combinations is warranted. This trial was registered at www.clinicaltrials.gov as NCT02684617.
MedTator: a serverless annotation tool for corpus development
Fu, Sunyang , Wang, Liwei , Liu, Sijia , Wen, Andrew , Liu, Hongfang , He, Huan , Fu, Sunyang , Wang, Liwei , Liu, Sijia , Wen, Andrew , Liu, Hongfang , He, Huan

Mayo Clinic

Bioinformatics | December 31, 2021 | Volume: 38 | Issue: 6 | Pages: 1776-1778

10.1093/bioinformatics/btab880 | PMID 34983060 Get It

AbstractSummaryBuilding a high-quality annotation corpus requires expenditure of considerable time and expertise, particularly for biomedical and clinical research applications. Most existing annotation tools provide many advanced features to cover a variety of needs where the installation, integration and difficulty of use present a significant burden for actual annotation tasks. Here, we present MedTator, a serverless annotation tool, aiming to provide an intuitive and interactive user interface that focuses on the core steps related to corpus annotation, such as document annotation, corpus summarization, annotation export and annotation adjudication.Availability and implementationMedTator and its tutorial are freely available from https://ohnlp.github.io/MedTator. MedTator source code is available under the Apache 2.0 license: https://github.com/OHNLP/MedTator.Supplementary informationSupplementary data are available at Bioinformatics online.
Carotid Intima-Media Thickness in Patients with Subclinical Hypothyroidism: A Prospective Controlled Study
Soto-García, Anally , Elizondo‐Riojas, Guillermo , Rodríguez‐Gutiérrez, René , Mancillas‐Adame, Leonardo , González‐González, José Gerardo , Mancillas-Adame, Leonardo G , González-González, José Gerardo

Mayo Clinic

Clinical and Investigative Medicine | December 31, 2021 | Volume: 44 | Issue: 4 | Pages: E39-E45

10.25011/cim.v44i4.37139 | PMID 34978774 Get It

Purpose The association between subclinical hypothyroidism (SCH) and cardiovascular risk, particularly with a TSH <10 µIU/ml, remains controversial. The objective of our study was to assess the association between SCH and cardiovascular risk through carotid intima-media thickness, and alternatively, to evaluate its change after treatment with levothyroxine. Methods A total of 54 individuals were included in the study: 18 with SCH; 18 with overt hypothyroidism (OH); and 18 healthy controls (HC). The carotid intima-media thickness was measured in each group. In SCH, follow-up was performed at three and six months after the start of levothyroxine treatment. Results The mean age of the total population at baseline was 35.8 years. The median TSH in SCH was 6.15 µIU/ml. The carotid intima-media thickness (mean and standard deviation) was greater in SCH in comparison to the HC group: right common carotid artery (RCCA), 0.486 ± 0.106 mm and 0.413 ± 0.075 mm in SCH and HC, respectively, p=0.01 and left common carotid artery (LCCA), 0.511 ± 0.144 mm and 0.427 mm ± 0.090 in SCH and HC, respectively, p=0.03). In patients with SCH, there was a decrease in the carotid intima-media thickness after treatment with levothyroxine (RCCA and LCCA, p <0.05 at three and six months). Conclusions There was an association between increased carotid intima-media thickness in patients with SCH in comparison with HC, even with a TSH <10 µIU/ml. The increase was reversed with levothyroxine therapy. The association of this increased thickness with important cardiovascular outcomes remains uncertain and should be evaluated in future studies.
The corona mortis: is it a rare and dangerous anomaly in adolescents undergoing periacteabular osteotomy?
Hu, Alan W. , McCarthy, James J. , Breitenstein, Rachel, Uchtman, Molly, Emery, Kathleen H., Whitlock, Patrick W. , Hu, Alan

Mayo Clinic

Journal of Hip Preservation Surgery | December 31, 2021 | Volume: 8 | Issue: 4 | Pages: 354-359

10.1093/jhps/hnab079 | PMID 35505810 Get It

ABSTRACT The corona mortis (CM) is a vascular connection between the obturator and external iliac or internal epigastric vessels that has historically been identified as a source of hemorrhage in pelvic surgery. However, its frequency, location, proximity to the osteotomies performed, vascular contributions and impact on blood loss in patients undergoing periacetabular osteotomy (PAO) are unknown. We sought to identify the frequency, origin, location relative to osteotomies performed during surgery and impact on blood loss of the CM. Preoperative magnetic resonance imaging (MRI) of the hips of 28 adolescent patients (56 hips) undergoing PAO was retrospectively reviewed for the presence of a CM. When identifiable, the size, nature (arterial or venous), orientation, position relative to the iliopectineal eminence (IPE) and associated estimated blood loss (EBL) were recorded. 75% (21/28) of patients possessed an identifiable, ipsilateral CM to the site of PAO, 90% of which were venous and 10% arterial. The vessel was typically 8.3 ± 3.8 mm medial and 11.1 ± 5.3 mm caudal from the anterosuperomedial edge of the IPE. There was no significant difference in the amount of EBL (519 ± 260 versus 694 ± 369 ml) or need for post-op transfusions (1/21 versus 0/7) between patients who possessed a CM and those who did not, respectively (P = 0.21). CM was more prevalent in this study than previously reported. However, the presence of an ipsilateral CM was not associated with an increase in EBL or transfusion during routine PAO surgery using modern surgical techniques.
In Mason Type-2 Radial Head Fracture, Surgical and Nonsurgical Treatment Did Not Differ for Functional Outcomes at 12 Months
O’Driscoll, Shawn, Rojas-Lievano, Jorge, O’Driscoll, Shawn W. , Liévano, Jorge Rojas , Fitzsimmons, James S , Rojas-Lievano, Jorge, Lievano, Jorge Rojas

Mayo Clinic

Journal of Bone and Joint Surgery | December 31, 2021 | Volume: 104 | Issue: 4 | Pages: 377-377

10.2106/jbjs.21.01483 | PMID 34971550 Get It

Association Between Arousals During Sleep and Hypertension Among Patients With Obstructive Sleep Apnea
Ren, Rong, Zhang, Ye, Yang, Linghui , Somers, Virend K. , Covassin, Naima , Tang, Xiangdong , Zhang, Ye , Somers, Virend K. , Tang, Xiangdong , Ren, Rong, Zhang, Ye, Yang, Linghui , Covassin, Naima

Mayo Clinic

Journal of the American Heart Association | December 31, 2021 | Volume: 11 | Issue: 1 | Pages: No page available

10.1161/jaha.121.022141 | PMID 34970921 Get It

Background Sleep fragmentation induced by repetitive arousals is a hallmark of obstructive sleep apnea (OSA). Sleep fragmentation has been linked to hypertension in community‐based studies, but it is unclear if this association is manifest in OSA. We aimed to explore whether frequent arousals from sleep modify the relationship between OSA and prevalent hypertension. Methods and Results A total of 10 102 patients with OSA and 1614 primary snorers were included in the study. Hypertension was defined on either direct blood pressure measures or diagnosis by a physician. Spontaneous, respiratory, and movement arousals were derived by polysomnography. Logistic regression models were used to estimate the associations between arousals and prevalent hypertension in patients with OSA and primary snorers. For every 10‐unit increase of total arousal index, odds of hypertension significantly increased in both the total sample (odds ratio [OR], 1.08; 95% CI, 1.03–1.14; P =0.002) and patients with OSA (OR, 1.10; 95% CI, 1.04–1.16; P <0.001), but not in the primary snoring group. Total arousal index was significantly associated with systolic blood pressure and diastolic blood pressure in the total sample (β=0.05 and β=0.06; P <0.001) and in patients with (β=0.05 and β=0.06; P <0.01), but not in primary snorers. In addition, a greater influence of respiratory events with arousals than respiratory events without arousals on blood pressure in OSA was also noted. Results were independent of confounders, including apnea‐hypopnea index and nocturnal hypoxemia. Conclusions We conclude that repetitive arousals from sleep are independently associated with prevalent hypertension in patients with OSA.
White matter changes in empirically derived incident MCI subtypes in the Mayo Clinic Study of Aging
Lundt, Emily S. , Mester, Carly , Albertson, Sabrina M., Raghavan, Sheelakumari , Graff‐Radford, Jonathan , Kremers, Walter K. , Petersen, Ronald C. , Bondi, Mark W. , Vemuri, Prashanthi , Mester, Carly T, Vemuri, Prashanthi , Kremers, Walter K , Machulda, Mary M. , Reid, Robert I. , Schwarz, Christopher G. , Jack, Clifford R. , Knopman, David S. , Mielke, Michelle M. , Lundt, Emily S

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | December 31, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/dad2.12269 | PMID 35005199 Get It

Abstract Introduction The aim of this study was to examine white matter hyperintensities (WMH) and fractional anisotropy (FA) in empirically derived incident mild cognitive impairment (MCI) subtypes. Methods We evaluated 188 participants with incident MCI in the Mayo Clinic Study of Aging (MCSA) identified as having one of four cluster‐derived subtypes: subtle cognitive impairment, amnestic, dysnomic, and dysexecutive. We used linear regression models to evaluate whole brain and regional WMH volumes. We examined fractional anisotropy (FA) on a subset of 63 participants with diffusion tensor imaging. Results Amnestic and dysexecutive subtypes had higher WMH volumes in differing patterns than cognitively unimpaired; the dysexecutive subtype had higher WMH than subtle cognitive impairment. There was widespread WM degeneration in long association and commissural fibers in the amnestic, dysnomic, and dysexecutive subtypes, and corpus callosum FA accounted for significant variability in global cognition. Discussion White matter changes likely contribute to cognitive symptoms in incident MCI.